- Home
- UTMD vs ENLV Comparison
UTMD vs ENLV Comparison
Compare UTMD & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UTMD | ENLV |
|---|---|---|
| Founded | 1978 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.1M | 196.2M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | UTMD | ENLV |
|---|---|---|
| Price | $67.84 | $0.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 8.5K | ★ 557.6K |
| Earning Date | 04-23-2026 | 05-29-2026 |
| Dividend Yield | ★ 1.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.48 | N/A |
| Revenue | ★ $38,520,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $51.27 | $0.66 |
| 52 Week High | $71.81 | $2.10 |
Technical Indicators
Market Signals| Indicator | UTMD | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 45.66 |
| Support Level | $60.23 | $0.81 |
| Resistance Level | $68.71 | $1.23 |
| Average True Range (ATR) | 1.68 | 0.08 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 43.81 | 57.88 |
Price Performance
Historical ComparisonAbout UTMD Utah Medical Products Inc.
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.